Evaxion Biotech announces the presentation of its novel precision vaccine concept at the 65th American Society of Hematology, ASH, Annual Meeting, taking place in San Diego, California, from December 9-12, 2023. Selected for an Oral Presentation – Evaxion has been chosen for an oral presentation from a competitive pool of greater than5000 submitted abstracts. The presentation will unveil a breakthrough achievement using the Company’s proprietary AI target discovery and development platform, AI-Immunology. Tailored Precision Vaccines – The precision vaccines are tailored to the specific tumor profiles and immune systems of patient groups. This marks a significant stride forward in addressing the complexities of cancers, including hematological malignancies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EVAX:
- Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
- Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy
- Evaxion Biotech presents proof-of-principle for its AI model
- Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak
- Evaxion Biotech announces initial Phase 2 data on EVX-01 vaccine